Gliosarcoma. A case of a long survivor

Abstract

S200reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S198-S207 reports of practical oncology and radiotherapy 1 8 ( 2 0 1 3 ) S198-S207 S201 temozolomide in monotherapy 150 mg/m 2 /D1-5 (1st cycle) and 200 mg/m 2 /D1-5 ending in December 2009. Currently has headaches that disappear with analgesia, with no signs of recurrence in serial MRI. Progression-free interval > 3 years. Discussion. First described in 1895, is a variant of glioblastoma multiforme (2-8%) with a glial and a sarcomatous component. With peak incidence between 50-70 years, male: female ratio of 1.4:1 and most common in the temporal lobe. The sarcomatous component can metastasize (15-30%, more than the glioblastoma multiforme) more frequently to spinal cord, lung, bone and lymph nodes and surrounding structures. The glial usually corresponds to glioblastoma, although sometimes described oligodendrogliomas or subependymomas. The survival ranges from 8 to 24 months. Rarely occur as multicentric tumors. Factors affecting overall survival are age at presentation, extent of resection, adjuvant radiotherapy and race, has been that men have more survival and tumor size also has an impact at this level. Conclusions. It is a rare tumor with a worse prognosis than glioblastoma multiforme, where a good surgical and adjuvant therapy with RTE + QT is a determining factor in overall survival. http://dx.